Complete financial analysis of Medexus Pharmaceuticals Inc. (MEDXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medexus Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Medigene AG (MDGEF) Income Statement Analysis – Financial Results
- Yatra Online, Inc. (YTRA) Income Statement Analysis – Financial Results
- Crealogix Holding AG (CLXN.SW) Income Statement Analysis – Financial Results
- Shanghai YongLi Belting Co., Ltd (300230.SZ) Income Statement Analysis – Financial Results
- Sun.King Technology Group Limited (0580.HK) Income Statement Analysis – Financial Results
Medexus Pharmaceuticals Inc. (MEDXF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.medexus.com
About Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.05M | 108.10M | 76.70M | 79.66M | 52.43M | 25.36M | 7.75M | 4.65M | 2.89M | 3.69M | 3.07M | 0.00 | 0.00 |
| Cost of Revenue | 53.54M | 48.06M | 38.77M | 37.66M | 22.99M | 10.38M | 3.85M | 2.08M | 998.43K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 59.51M | 60.04M | 37.93M | 42.01M | 29.44M | 14.98M | 3.90M | 2.57M | 1.89M | 3.69M | 3.07M | 0.00 | 0.00 |
| Gross Profit Ratio | 52.64% | 55.54% | 49.45% | 52.73% | 56.15% | 59.08% | 50.37% | 55.24% | 65.44% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 8.04M | 2.94M | 5.87M | 4.60M | 1.10M | 0.00 | 0.00 | 0.00 | 0.00 | 542.62K | 1.38M | 0.00 | 0.00 |
| General & Administrative | 27.86M | 36.86M | 34.52M | 19.28M | 11.77M | 5.64M | 1.58M | 2.15M | 2.72M | 1.21M | 2.02M | 149.56K | 136.14 |
| Selling & Marketing | 10.58M | 11.39M | 9.51M | 16.89M | 17.16M | 9.97M | 4.51M | 2.95M | 2.48M | 3.15M | 4.70M | 0.00 | 0.00 |
| SG&A | 38.44M | 48.25M | 44.03M | 36.17M | 28.93M | 15.62M | 6.09M | 5.10M | 5.20M | 4.36M | 6.72M | 149.56K | 136.14 |
| Other Expenses | 2.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.72M | 51.55M | 50.30M | 41.27M | 30.48M | 15.66M | 6.10M | 5.12M | 5.28M | 4.90M | 8.10M | 149.56K | 136.14 |
| Cost & Expenses | 102.26M | 99.61M | 89.08M | 78.93M | 53.47M | 26.04M | 9.95M | 7.20M | 6.28M | 4.90M | 8.10M | 149.56K | 136.14 |
| Interest Income | 0.00 | 0.00 | 0.00 | 3.00K | 205.89K | 161.72K | 30.82K | 29.96K | 31.95K | 23.21K | 49.23K | 0.00 | 0.00 |
| Interest Expense | 13.36M | 13.61M | 12.22M | 9.82M | 6.44M | 2.90M | 918.90K | 501.78K | 732.52K | 269.44K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.81M | 8.05M | 7.71M | 7.90M | 5.26M | 2.38M | 231.16K | 51.87K | 113.48K | 88.12K | 0.00 | 0.00 | 0.00 |
| EBITDA | 19.28M | 14.65M | 15.16M | -23.61M | 7.04M | 159.00K | -2.06M | -697.72K | -1.15M | -3.85M | -4.88M | -2.02M | -136.14 |
| EBITDA Ratio | 17.05% | 13.48% | -8.12% | 8.43% | 3.25% | 5.58% | -25.62% | -59.93% | -113.69% | -31.76% | -159.09% | 0.00% | 0.00% |
| Operating Income | 10.79M | 7.61M | -15.00M | -1.38M | -5.41M | -4.39M | -2.18M | -592.05K | -1.03M | -1.21M | -4.88M | -149.56K | -136.14 |
| Operating Income Ratio | 9.55% | 7.04% | -19.55% | -1.73% | -10.32% | -17.32% | -28.09% | -12.72% | -35.72% | -32.78% | -159.09% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.69M | -12.66M | 11.18M | -30.13M | 244.00K | -477.99K | -501.00K | -584.12K | -431.64K | 38.83K | -117.08K | 0.00 | 0.00 |
| Income Before Tax | 106.00K | -5.04M | -3.82M | -31.50M | -5.19M | -4.72M | -2.70M | -1.37M | -1.77M | -3.22M | -5.00M | -149.56K | -136.14 |
| Income Before Tax Ratio | 0.09% | -4.66% | -4.98% | -39.54% | -9.89% | -18.60% | -34.79% | -29.51% | -61.31% | -87.14% | -162.90% | 0.00% | 0.00% |
| Income Tax Expense | 320.00K | -6.26M | -941.00K | -3.24M | -790.44K | 166.29K | 918.90K | 501.78K | 732.52K | 269.44K | 0.00 | 0.00 | 0.00 |
| Net Income | -214.00K | 1.22M | -2.88M | -28.26M | -4.40M | -4.88M | -2.70M | -1.37M | -1.77M | -3.22M | -5.00M | -149.56K | -136.14 |
| Net Income Ratio | -0.19% | 1.13% | -3.75% | -35.48% | -8.39% | -19.26% | -34.79% | -29.51% | -61.31% | -87.14% | -162.90% | 0.00% | 0.00% |
| EPS | -0.01 | 0.06 | -0.15 | -1.86 | -0.31 | -0.49 | -0.47 | -0.28 | -0.37 | -0.67 | -0.07 | -0.27 | 0.00 |
| EPS Diluted | -0.01 | 0.06 | -0.14 | -1.86 | -0.31 | -0.49 | -0.47 | -0.28 | -0.37 | -0.67 | -0.07 | -0.27 | 0.00 |
| Weighted Avg Shares Out | 22.32M | 19.98M | 19.45M | 15.20M | 14.36M | 9.91M | 5.68M | 4.84M | 4.83M | 4.80M | 72.06M | 544.00K | 177.78K |
| Weighted Avg Shares Out (Dil) | 22.32M | 20.52M | 19.86M | 15.20M | 14.36M | 9.91M | 5.68M | 4.84M | 4.83M | 4.80M | 72.06M | 544.00K | 177.78K |
Medexus Pharmaceuticals doubles fiscal 3Q revenue to record C$31.5M
Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) (FRA:P731) announced its fiscal third quarter results after the bell Monday, revealing record quarterly revenue of C$31.5 million in the three months ended December 31. The company nearly doubled its revenue year-over-year from C$16.2 million...
Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021
Management to host conference call at 8:00 AM Eastern Time on Tuesday, March 2, 2021 Management to host conference call at 8:00 AM Eastern Time on Tuesday, March 2, 2021
Medexus begins commercial launch of tumor imaging powder Gleolan in Canada
Medexus Pharmaceuticals Inc (TSXV:MDP) (OTCQX:MEDXF) (FRA:P731) has initiated the Canadian commercial launch of Gleolan, a powder-based optical imaging agent taken orally by patients to help surgeons identify brain and spinal cord tumors called gliomas. Gleolan is an imaging agent that...
Medexus Pharmaceuticals has a potential company-maker in Treosulfan
Rapidly growing, North American focused, specialty pharmaceutical company Diversified product portfolio and expanding product pipeline Highly scalable business platform with significant cash flow potential What Medexus Pharmaceuticals does: Toronto-based Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) is a specialty pharmaceutical company created...
Stifel GMP boosts target price of Medexus by 130%, saying Treosulfan could double company valuation
Stifel GMP is boosting its price target on Medexus Pharmaceuticals Inc (CVE:MDP) (OTCMKTS:MEDXF) to C$17.50, a whopping 130% increase over the $7.60 it had previously stated. The increase is thanks to new developments related to its lead drug Treosulfan, an...
Medexus Pharmaceuticals closes previously announced 'bought deal' public offering total gross proceeds of approximately $32,529,992
Medexus Pharmaceuticals Inc. (CVE:MDP) said it has closed its previously announced bought deal public offering of 4,581,689 units at a price of $7.10 each for total gross proceeds of approximately $32,529,992, including 597,611 units sold under the full exercise of the...
Medexus Announces Closing of $32.5 Million Public Offering, Including Exercise in Full of Over-Allotment Option
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side
TORONTO, CHICAGO and MONTREAL, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being...
Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States
Orphan Designated Drug with August 2021 PDUFA date
Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®
TORONTO, CHICAGO and MONTREAL, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has renewed and expanded its distribution agreement for NYDA®, a market leading treatment for...
Source: https://incomestatements.info
Category: Stock Reports